Clinical Trials Logo

Filter by:
NCT ID: NCT01577173 Completed - Clinical trials for Head and Neck Cancer

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

Start date: July 2012
Phase: Phase 2
Study type: Interventional

This phase II, open-label, randomized study will evaluate the efficacy and safety of MEHD7945A versus cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck who have progressed during or following platinum-based chemotherapy. Patients will be randomized to receive either MEHD7945A 1100 mg intravenously (iv) every 2 weeks or cetuximab 400 mg/m2 iv loading dose followed by 250 mg/m2 iv weekly. Patients treated with cetuximab (Arm B) may cross-over to MEHD7945A (Arm A) upon central confirmation of progressive disease and upon meeting eligibility criteria. Anticipated time on study treatment is until disease progression or intolerable toxicity occurs.

NCT ID: NCT01577082 Completed - Asthma Clinical Trials

Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients

Start date: April 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to show the superiority of CHF 1535 (BDP/FF) pMDI over BDP HFA pMDI in terms of lung function considering change from baseline to the entire treatment period in average pre-dose morning PEF in adult asthmatic patients not adequately controlled on high doses of ICS or on medium dose of ICS+LABA.

NCT ID: NCT01576861 Completed - Clinical trials for Chronic Heart Failure

Long-Term Efficacy and Safety of Growth Hormone Replacement Therapy in Chronic Heart Failure

Start date: January 2007
Phase: Phase 2
Study type: Interventional

After the encouraging results of 6 months of Growth Hormone Replacement Therapy in Patients With Chronic Heart Failure and Coexisting Growth Hormone Deficiency (NCT00591760) the investigators wanted to collect data about the long-term efficacy and safety of this kind of therapy.

NCT ID: NCT01576666 Completed - Gastric Cancer Clinical Trials

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Start date: July 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies. This study will also learn more about how the combination of these two investigational drugs may work for patients with certain cancers (specifically metastatic breast cancer, advanced pancreatic adenocarcinoma, metastatic colorectal cancer and recurrent glioblastoma multiforme).

NCT ID: NCT01576341 Completed - Clinical trials for Chronic Kidney Disease

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)

SENSE
Start date: April 2012
Phase: Phase 3
Study type: Interventional

The study will assess the immunogenicity, safety, and efficacy of HX575 epoetin alfa administered subcutaneously (s.c.) in patients suffering from anemia due to chronic kidney disease (CKD)

NCT ID: NCT01575431 Completed - Clinical trials for Coronary Artery Disease

Progenitor Cells Role in Restenosis and Atherosclerosis

PROCREATION
Start date: April 2012
Phase:
Study type: Observational

The aim of this study is to prospectively investigate the relationship of circulating endothelial progenitor cells at time of percutaneous coronary intervention to the subsequent development of in-stent restenosis or progression of coronary atherosclerosis.

NCT ID: NCT01575353 Completed - Respiratory Failure Clinical Trials

Nasal High-flow Versus Venturi Mask Oxygen Therapy in the Post-extubation Period

Start date: December 2010
Phase: N/A
Study type: Interventional

The aim of the study is to compare two devices for oxygen therapy, nasal high-flow and Venturi mask, in critically ill patients in the post-extubation period. The hypothesis is that nasal high-flow may be superior to the Venturi mask in terms of oxygenation

NCT ID: NCT01574716 Completed - Clinical trials for Metastatic Soft Tissue Sarcoma

Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

SOURCE
Start date: August 7, 2012
Phase: Phase 2
Study type: Interventional

This study is being done to see if MORAb-004 increases the effectiveness of the chemotherapies gemcitabine and docetaxel in people with metastatic Soft Tissue Sarcoma.

NCT ID: NCT01574482 Completed - Clinical trials for Mildly Hypercholesterolemic Subjects

Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (Italy)

Start date: January 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the cholesterol lowering effect of a drinkable low fat fermented milk enriched with plant sterol after 3 and 6 weeks of daily consumption in mildly hypercholesterolemic people treated or not by statins

NCT ID: NCT01574209 Completed - Clinical trials for Irritable Bowel Syndrome

Gut Peptides and Intestinal Permeability in Celiac Disease and Irritable Bowel Syndrome

PPCD
Start date: April 2012
Phase: N/A
Study type: Observational

It is well known that the intestinal barrier is altered in celiac disease (CD), an autoimmune disease that develops in genetically predisposed subjects exposed to ingestion of wheat gliadin and of related prolamines of barley and rye. More recently, defective epithelial barrier has been implicated in the pathogenesis of other conditions such as irritable bowel syndrome (IBS). At present IBS is still considered a functional condition although low-grade inflammation has been associated with its manifestation, particularly that following infection. Different substances have been implicated in the (dis)regulation of intestinal barrier, among them zonulin seems to play a key role. Other gastrointestinal peptides are GPL-2, Ghrelin, and Epidermal growth factor (EGF). In order to shed light on the hormonal regulation of intestinal barrier function in celiac patients before undergoing a gluten free diet and possible differences with those of IBS patients, in the present study the investigators will apply the non-invasive lactulose/mannitol permeability test toward the evaluation of intestinal damage. The pattern of intestinal permeability and the GI peptides concentration will be compared in celiac patients, IBS patients and healthy controls.